1. Diabetes Disease Indicator
2. Global Market Analysis
2.1 Overview of Global Diabetes Drug Market, 2008
2.2 Global Insulin Supply
2.3 Key Trends of Diabetes Markets Worldwide
2.4 Global Diabetes Drug Demand Analysis
2.4.1 Demand Analysis
2.4.1.1 By Age Group
2.4.1.2 By Patients taking Insulin
2.5 Diabetes Market Growth by Products, 2008
3. Insulin Delivery Market
3.1 Market Size And Growth Rate
3.1.1 USA
3.1.2 South and Central America
3.1.3 Western Pacific
3.1.4 Europe
3.1.5 Asia
3.2 Comparative Study of Traditional and Non-Traditional Therapeutic Market
3.2.1 Insulin Syringes
3.2.2 Insulin Pens
3.2.3 Insulin Jet Injectors
3.2.4 Oral Drug Delivery
3.2.5 Pump Therapy
3.3 Non-Injectable Insulin Market
3.3.1 Market Overview
3.3.2 Worldwide Products Sales
3.4 Market Projection: Future Ahead by 2008
4. Treatment of Diabetes
4.1 Gene Therapy
4.2 Pump Therapy
4.3 Xenotransplantion
4.4 Recombinant Human Insulin-like Growth Factor-I (rhIGF-I)
4.5 Islet Cell Transplant
4.6 Drugs for Type 2 Diabetes
4.6.1 Dual PPARy/ Agonists
4.6.2 Orlistat
4.6.3 Insulin Secretagogues
4.7 Therapy for Type 2 Diabetes
4.7.1 Metformin: Increase Insulin Sensitivity
4.7.2 Increase Circulating Insulin
4.7.3 Exogenous Insulin
4.8 Diabetes Monitoring Devices
4.8.1 Pain Free Glucose Tests
4.8.2 Continuous Monitoring Device
5. Recent Trends and Developments
6. Key Drivers
6.1 Eli Lilly and Company
6.2 Novo Nordisk A/S
6.3 Sanofi-Aventis
6.4 GlaxoSmithKline plc
6.5 Amylin Pharmaceuticals, Inc.
7. Outlook
List of Figures:
Figure 1-1: Prevalence of Diabetes in the United States
Figure 1-2: Diabetes Mellitus– Number of Cases (in Millions)
Figure 2-1: Sales Forecasts for Global Diabetes Market, 2010
Figure 2-2: World Diabetes Marketed and Forecasts, 2008
Figure 2-3: Insulin Supply for People with Type-1 Diabetes by Region
Figure 2-4: World Diabetes Market, 2008
Figure 2-5: Worldwide Sales of Diabetes Drug (%) by Region, 2004
Figure 2-6: Age Distribution of Oral Antidiabetics by Prescriptions
Figure 2-7: Co-Prescribing of Leading Antidiabetics in USA by Prescriptions
Figure 2-8: Co-Prescribing of Leading Antidiabetics in UK by Prescriptions
Figure 2-9: Total Numbers of Patients using Insulin Pumps (1998-2005)
Figure 3-1: United States- Estimated Total Prevalence of Diabetes (by age group), 2005
Figure 3-2: United States- Estimated Total Prevalence of Diabetes (by race/ethnicity), 2005
Figure 3-3: United States- Estimated Number of New Cases of Diabetes (by age group), 2005
Figure 3-4: United States- Distribution of Age at Diagnosis of Diabetes among Adults Aged 18–79 Years, 2004
Figure 3-5: United States- Number of Persons with Diagnosed Diabetes (2000–2004)
Figure 3-6: United States- Age adjusted prevalence of Diagnosed Diabetes per 100 Population by Sex (1980–2004)
Figure 3-7: United States- Age specific prevalence of Diagnosed Diabetes, by Race/Ethnicity and Sex (2004)
Figure 3-8: Percentage of People with Diabetes receiving Preventive Care, 2004
Figure 3-9: United States- Treatment of Diabetes with Insulin or Oral Medications (2001–2003)
Figure 3-10: US Insulin Market
Figure 3-11: Age-Standardized prevalence of Diagnosed and Undiagnosed Diabetes and Impaired Fasting Glucose in the U.S. Population (by Sex and Ethnic groups)
Figure 3-12: Worldwide Insulin Syringes Market (by Demographic Share)
Figure 3-13: Estimated Growth in the Prevalence of Diabetes (by Regions), 2025
List of Tables:
Table 2-1: Trends In Prescription Drug Use Among Patients with Type -2 Diabetes (1997-2004)
Table 2-2: Total Prevalence of Diabetes Worldwide, 2002
Table 2-3: Worldwide Diabetes Market (2002-2008)
Table 3-1: South and Central America - Diabetes patients (2003-2025)
Table 3-2: South and Central America - Type 1 Diabetes patients (0-14 years) for 2003
Table 3-3: Western Pacific - Diabetes patients (2003-2025)
Table 3-4: Western Pacific - Type 1 Diabetes patients (0-14 years) for 2003
Table 3-5: Europe - Diabetes patients (2003-2025)
Table 3-6: Europe - Type 1 Diabetes patients (0-14 years) for 2003
Table 3-7: Asia - Diabetes patients (2003-2025)
Table 3-8: Asia - Type 1 Diabetes patients (0-14 years) for 2003
Table 3-9: Worldwide Drug Delivery Systems (2003-2008)
Table 6-1: Eli Lilly and Company- Annual Income Statements (Million $ US), 2003-2005
Table 6-2: Eli Lilly and Company- Segment Wise Information Year Ended December 31 for Eli Lilly (2003-2005)
Table 6-3: Novo Nordisk A/S- Annual Income Statements (in Million US Dollars except share amounts)
Table 6-4: Sanofi-Aventis- Annual Income Statements (in Million US Dollars except share amounts)
Table 6-5: GlaxoSmithKline plc- Annual Income Statements (in Million US Dollars except share amounts)
Table 6-6: Amylin Pharmaceuticals, Inc.- Annual Income Statements (in Million US Dollars except share amounts)
